Schulze-Gahmen U, Brandsen J, Jones H D, Morgan D O, Meijer L, Vesely J, Kim S H
Department of Chemistry, University of California, Berkeley 94720, USA.
Proteins. 1995 Aug;22(4):378-91. doi: 10.1002/prot.340220408.
Cyclin-dependent kinases (CDKs) are conserved regulators of the eukaryotic cell cycle with different isoforms controlling specific phases of the cell cycle. Mitogenic or growth inhibitory signals are mediated, respectively, by activation or inhibition of CDKs which phosphorylate proteins associated with the cell cycle. The central role of CDKs in cell cycle regulation makes them a potential new target for inhibitory molecules with anti-proliferative and/or anti-neoplastic effects. We describe the crystal structures of the complexes of CDK2 with a weakly specific CDK inhibitor, N6-(delta 2-isopentenyl)adenine, and a strongly specific inhibitor, olomoucine. Both inhibitors are adenine derivatives and bind in the adenine binding pocket of CDK2, but in an unexpected and different orientation from the adenine of the authentic ligand ATP. The N6-benzyl substituent in olomoucine binds outside the conserved binding pocket and is most likely responsible for its specificity. The structural information from the CDK2-olomoucine complex will be useful in directing the search for the next generation inhibitors with improved properties.
细胞周期蛋白依赖性激酶(CDK)是真核细胞周期的保守调节因子,不同的异构体控制细胞周期的特定阶段。促有丝分裂或生长抑制信号分别通过激活或抑制CDK来介导,CDK使与细胞周期相关的蛋白质磷酸化。CDK在细胞周期调控中的核心作用使其成为具有抗增殖和/或抗肿瘤作用的抑制性分子的潜在新靶点。我们描述了CDK2与弱特异性CDK抑制剂N6-(δ2-异戊烯基)腺嘌呤和强特异性抑制剂olomoucine形成的复合物的晶体结构。两种抑制剂都是腺嘌呤衍生物,结合在CDK2的腺嘌呤结合口袋中,但与天然配体ATP的腺嘌呤的方向不同且出乎意料。olomoucine中的N6-苄基取代基结合在保守结合口袋之外,很可能是其特异性的原因。来自CDK2-olomoucine复合物的结构信息将有助于指导寻找具有改进特性的下一代抑制剂。